Mousavi Niri Neda, Memarnejadian Arash, Pilehvar-Soltanahmadi Younes, Agha Sadeghi Mohammadreza, Mahdavi Mehdi, Kheshtchin Nasim, Arab Samaneh, Namdar Afshin, Jadidi Farhad, Zarghami Nosratollah, Hajati Jamshid
*Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz Departments of †Hepatitis and AIDS ‡Immunology, Pasteur Institute of Iran Departments of §Immunology, School of Medicine ∥Molecular Medicine, School of Advanced Technologies in Medicine #Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran ¶Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Immunother. 2016 Sep;39(7):269-75. doi: 10.1097/CJI.0000000000000133.
The critical role of regulatory T (Treg) cells in dampening immune responses against tumor cells is apparent. Therefore, several methods have been introduced for eliminating Treg. Among them, inducing immune responses against Treg cells expressing Foxp3 transcription factor is a hopeful approach to decrease the frequency of Tregs. In current study, we used the chimeric FoxP3-Fc(IgG) fusion construct/protein to effectively stimulate the immune responses against Treg cells.
Previously constructed FoxP3-Fc(IgG) DNA vaccine and its protein counterpart were injected into C57BL/6 mice in a prime/boost regimen. After 2 weeks, the mice were killed to measure the frequency of Tregs in their spleens, as well as analyze their specific cytokine production, T-cell proliferation, and CD8 T-cell cytotoxicity against FoxP3 protein.
FACS analysis of FoxP3 CD4 cells in splenocytes revealed the efficiency of FoxP3 DNA-prime protein-boost strategy to decrease the Treg cells and further showed considerable superiority of Fc(IgG) fusion strategy. This significant reduction in Treg frequency was also concomitant with higher FoxP3-specific CTL and Th1 responses in FoxP3-Fc vaccinated animals.
Prime/boost vaccination against FoxP3 in addition to enhanced antigen presentation by means of Fc fusion strategy could be successfully considered for Treg depletion studies. Validity of this approach should be experimentally tested in preclinical tumor models.
调节性T(Treg)细胞在抑制针对肿瘤细胞的免疫反应中发挥的关键作用是显而易见的。因此,已经引入了几种消除Treg的方法。其中,诱导针对表达Foxp3转录因子的Treg细胞的免疫反应是降低Treg频率的一种有希望的方法。在当前的研究中,我们使用嵌合的FoxP3-Fc(IgG)融合构建体/蛋白来有效刺激针对Treg细胞的免疫反应。
将先前构建的FoxP3-Fc(IgG)DNA疫苗及其蛋白对应物以初免/加强免疫方案注射到C57BL/6小鼠体内。2周后,处死小鼠以测量其脾脏中Treg的频率,并分析其特异性细胞因子产生、T细胞增殖以及CD8 T细胞对FoxP3蛋白的细胞毒性。
对脾细胞中FoxP3 CD4细胞的流式细胞术分析揭示了FoxP3 DNA初免-蛋白加强策略降低Treg细胞的效率,并进一步显示了Fc(IgG)融合策略的显著优势。Treg频率的显著降低还伴随着FoxP3-Fc疫苗接种动物中更高的FoxP3特异性CTL和Th1反应。
除了通过Fc融合策略增强抗原呈递外,针对FoxP3的初免/加强免疫接种可成功用于Treg耗竭研究。这种方法的有效性应在临床前肿瘤模型中进行实验测试。